AxoGen (NASDAQ:AXGN) posted its quarterly earnings results on Sunday. The medical equipment provider reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.08, MarketWatch Earnings reports. AxoGen had a negative net margin of 22.98% and a negative return on equity of 19.83%.
AXGN traded up $0.21 on Tuesday, reaching $21.40. The company had a trading volume of 797,124 shares, compared to its average volume of 264,749. The business has a 50 day simple moving average of $19.02 and a 200 day simple moving average of $14.98. The company has a market cap of $869.25 million, a price-to-earnings ratio of -33.97 and a beta of 0.71. The company has a debt-to-equity ratio of 0.42, a quick ratio of 6.81 and a current ratio of 7.45. AxoGen has a 52-week low of $7.16 and a 52-week high of $22.89.
A number of brokerages have weighed in on AXGN. Cantor Fitzgerald increased their target price on shares of AxoGen from $16.00 to $23.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 12th. SVB Leerink increased their target price on shares of AxoGen from $23.00 to $27.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Canaccord Genuity increased their target price on shares of AxoGen from $20.00 to $21.00 and gave the stock a “hold” rating in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. AxoGen currently has a consensus rating of “Buy” and an average price target of $23.75.
AxoGen, Inc, together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Recommended Story: How to use beta for portfolio diversification
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.